Compare SHIP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | IFRX |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | Greece | Germany |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.9M | 303.4M |
| IPO Year | 2008 | 2017 |
| Metric | SHIP | IFRX |
|---|---|---|
| Price | $16.92 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $6.25 |
| AVG Volume (30 Days) | 276.1K | ★ 873.9K |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.21 | $0.78 |
| 52 Week High | $18.48 | $2.95 |
| Indicator | SHIP | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.19 | 40.66 |
| Support Level | $13.60 | $1.58 |
| Resistance Level | N/A | $1.94 |
| Average True Range (ATR) | 0.79 | 0.12 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 72.20 | 21.35 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.